Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Uhm, Ji eun | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Sun, Jong-mu | - |
dc.contributor.author | Sohn, Insuk | - |
dc.contributor.author | Kim, Seon Woo | - |
dc.contributor.author | Jung, Sin-Ho | - |
dc.contributor.author | Park, Yeon Hee | - |
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.date.accessioned | 2022-07-16T16:57:34Z | - |
dc.date.available | 2022-07-16T16:57:34Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/166441 | - |
dc.description.abstract | Purpose: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib and erlotinib was evaluated as the second-line therapy for advanced non-small cell lung cancer (NSCLC). Patients and methods: Patients with locally advanced, metastatic stage IIIB/IV NSCLC who failed first-line chemotherapy and had either EGFR mutation or at least two out of three clinical factors associated with higher incidence of EGFR mutations (female, adenocarcinoma histology, and never-smoker) were eligible. Results: A total of 96 (48 per arm) patients were randomly assigned to gefitinib- or erlotinib-arm, respectively. Baseline characteristics were well-balanced between the two arms. The response rates (RR) were 47.9% in the gefitinib arm and 39.6% in the erlotinib arm. Median PFS was 4.9 months (95% CI, 1.3-8.5) in the gefitinib arm and 3.1 months (95% Cl, 0.0-6.4) in the erlotinib arm. The most common grade 3/4 toxicity was skin rash. Exploratory analyses showed that there was no significant difference in RR and PFS in the gefitinib arm compared to the erlotinib arm (RR (%) 47.9 vs. 39.6, p = 0.269; median survival (months) 4.9 vs. 3.1, p = 0.336). There was no significant difference in QOL between the two arms. Conclusion: Both gefitinib and erlotinib showed effective activity and tolerable toxicity profiles as second-line treatment for the selected population of NSCLC. We may consider conducting a phase III trial to directly compare the efficacy and toxicity between gefitinib and erlotinib in an enriched patient population. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.title | Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Uhm, Ji eun | - |
dc.identifier.doi | 10.1016/j.lungcan.2011.05.022 | - |
dc.identifier.scopusid | 2-s2.0-83555166254 | - |
dc.identifier.wosid | 000299450600012 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, v.75, no.1, pp.82 - 88 | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.citation.title | LUNG CANCER | - |
dc.citation.volume | 75 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 82 | - |
dc.citation.endPage | 88 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | PLATINUM-BASED CHEMOTHERAPY | - |
dc.subject.keywordPlus | PREVIOUSLY TREATED PATIENTS | - |
dc.subject.keywordPlus | RECEPTOR TYROSINE KINASE | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | SENSITIVITY | - |
dc.subject.keywordAuthor | Gefitinib | - |
dc.subject.keywordAuthor | Erlotinib | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0169500211003199?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.